Alzamend Neuro, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Alzamend Neuro, Inc. annual/quarterly Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q4 2023.
  • Alzamend Neuro, Inc. Share-based Payment Arrangement, Expense for the quarter ending January 31, 2024 was $187K, a 87.6% decline year-over-year.
  • Alzamend Neuro, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $956K, a 73.3% decline from 2022.
  • Alzamend Neuro, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.58M, a 18.7% decline from 2021.
  • Alzamend Neuro, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4.41M, a 82.8% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $187K -$1.32M -87.6% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-25
Q3 2023 $318K -$397K -55.5% Aug 1, 2023 Oct 31, 2023 10-Q 2023-12-15
Q1 2023 $3.58M $491K -$766K -60.9% Feb 1, 2023 Apr 30, 2023 10-K 2024-07-30
Q4 2022 $4.35M $1.51M +$378K +33.4% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-25
Q3 2022 $3.97M $716K -$565K -44.1% Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-15
Q2 2022 $4.54M $867K +$128K +17.3% May 1, 2022 Jul 31, 2022 10-Q 2022-09-13
Q1 2022 $4.41M $1.26M +$582K +86.2% Feb 1, 2022 Apr 30, 2022 10-K 2023-07-27
Q4 2021 $3.83M $1.13M +$556K +96.6% Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-15
Q3 2021 $3.27M $1.28M +$711K +125% Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-12
Q2 2021 $2.56M $740K +$148K +25.1% May 1, 2021 Jul 31, 2021 10-Q 2022-09-13
Q1 2021 $2.41M $676K Feb 1, 2021 Apr 30, 2021 10-K 2022-07-19
Q4 2020 $575K Nov 1, 2020 Jan 31, 2021 10-Q 2022-03-15
Q3 2020 $569K Aug 1, 2020 Oct 30, 2020 10-Q 2021-12-13
Q2 2020 $591K May 1, 2020 Jul 31, 2020 10-Q 2021-09-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.